GLP-1 Insurance Coverage 2026: Medicare, Employer Plans, Appeals & Alternatives

The 2026 GLP-1 Coverage Landscape at a Glance

Coverage for GLP-1 weight loss medications has expanded meaningfully since 2023, but remains uneven across plan types. The landmark SELECT trial — which showed semaglutide reduced major adverse cardiovascular events by 20% in people with obesity and established heart disease (Lincoff et al., NEJM 2023) — was the catalyst that pushed Medicare and many commercial insurers to begin covering these drugs beyond just type 2 diabetes.

Despite that progress, the majority of Americans with obesity still face barriers: formulary exclusions, high prior authorization burdens, expensive cost-sharing, or outright plan-level bans on weight-loss medications. Understanding which coverage tier applies to your situation is the essential first step.

For a broader overview of what GLP-1 medications cost across all access pathways, see our complete weight loss injection cost guide. If you already know you won't have coverage and want the most affordable route, our cheapest GLP-1 options for 2026 compares every major pathway side by side.

Medicare Part D: What Changed in 2026

Medicare Part D has historically excluded weight-loss medications under the "weight loss exclusion" embedded in the Social Security Act. That exclusion still stands in 2026 — Medicare cannot cover a drug prescribed solely for weight reduction. However, a significant carve-out now exists for semaglutide in a specific population.

The SELECT Trial Carve-Out

In 2024, CMS updated guidance to allow Medicare Part D coverage for Wegovy (semaglutide 2.4mg) when prescribed to patients who meet all three of these conditions:

1. Body mass index (BMI) of 27 or higher (overweight or obese)
2. Established atherosclerotic cardiovascular disease (prior heart attack, stroke, or documented ASCVD)
3. Prescribed Wegovy (the obesity-labeled semaglutide product specifically)

Medicare Part D Cost-Sharing in 2026

The Inflation Reduction Act's $2,000 out-of-pocket cap on Part D costs became fully effective in 2025. For Medicare beneficiaries who qualify for GLP-1 coverage, this cap limits annual drug spending to $2,000. However, the monthly cost-sharing before reaching the cap can still be substantial — typically $50–$150/month in the coverage phase depending on plan tier placement. Low-income subsidy (Extra Help) beneficiaries may pay significantly less.

For detailed information about qualifying for GLP-1 treatment under Medicare, see our guide to how to get a GLP-1 prescription and what documentation your provider needs to submit.

Employer Insurance: The Uneven Landscape

Employer-sponsored plans represent the most variable terrain for GLP-1 coverage. Unlike Medicare with its statutory rules, each employer plan can independently decide whether to cover weight-loss medications, which drugs to include, what prior authorization criteria to apply, and how to tier them on the formulary.

A 2025 KFF survey found that approximately 42% of large employers (1,000+ employees) cover at least one GLP-1 medication for obesity. Among small employers (fewer than 200 employees), that figure dropped to roughly 18%. Cost is the primary driver of non-coverage: Wegovy and Zepbound carry annual list prices exceeding $13,000, and even with negotiated rebates, they are among the most expensive therapeutic categories per member per year.

How to Check Your Employer Coverage

1. 1.Review your Summary of Benefits and Coverage (SBC): Available on the plan portal or from HR. Look for "obesity," "weight management," or "anti-obesity medications" under excluded benefits.
2. 2.Check the formulary: Search for semaglutide, tirzepatide, Wegovy, Ozempic, Mounjaro, or Zepbound on your plan's drug list. Note the tier and whether PA or step therapy is required.
3. 3.Call member services: Ask specifically: "Is the anti-obesity medication benefit excluded? What are the prior authorization criteria for semaglutide for weight loss?"
4. 4.Confirm the indication matters: Some plans cover semaglutide for diabetes (Ozempic) but exclude it for weight loss (Wegovy) even if your provider wants to prescribe it for obesity.

Advocating for Coverage at Open Enrollment

If your current plan excludes GLP-1 weight-loss coverage, open enrollment is the primary opportunity to change plans or advocate for benefit design changes. Strategies include:

• Submitting a written request to HR or benefits committee citing the ROI data on GLP-1 coverage (reduced hospitalization, CVOT outcomes)
• Requesting that the plan add a "carve-in" for GLP-1s with managed utilization controls (PA, step therapy)
• Comparing plan options at open enrollment — some marketplace alternatives or supplemental benefits packages include anti-obesity medication coverage

Prior Authorization: The Step-by-Step Process

Prior authorization (PA) is required by the vast majority of plans that do cover GLP-1 medications for weight loss. The PA process can be frustrating, but understanding exactly what insurers look for dramatically improves approval rates.

What Most Plans Require for PA Approval

PA Submission Best Practices

Your provider's office submits the PA, but you can meaningfully improve outcomes by preparing:

1. 1.Download the plan's current PA criteria document (available on the insurer's provider portal) and share it with your provider before the appointment
2. 2.Ensure all comorbidities are coded and documented in the most recent chart note — an undocumented condition cannot support a PA
3. 3.Ask your provider to write the medical necessity letter addressing each criterion in the plan's policy language, not generic obesity statistics
4. 4.Follow up with both the insurer and your provider's PA coordinator within 5–7 business days if you receive no determination notice

For a dedicated deep-dive on prior authorization strategy, read our prior authorization guide for GLP-1 approval.

Appeals Strategy: Reversing a GLP-1 Denial

An initial PA denial is not necessarily the final answer. Studies from the Kaiser Family Foundation and CMS data consistently show that patients who appeal insurance denials succeed in a meaningful percentage of cases — yet the vast majority of denied patients never file any appeal.

Four-Stage Appeals Pathway

Writing a Strong Appeal Letter

Our dedicated article on appealing GLP-1 insurance denials includes a sample letter template and guidance on how to handle each specific denial type.

HSA and FSA: Tax-Advantaged Paths to GLP-1 Access

Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) offer an underutilized pathway to reduce the effective cost of GLP-1 medications, even when insurance won't cover them. Because contributions are pre-tax, using an HSA or FSA to purchase medications or pay for telehealth visits provides an effective discount equal to your marginal tax rate — often 22–32% for most working adults.

What Qualifies as an HSA/FSA Expense

• Prescription GLP-1 medications (brand-name or compounded) prescribed by a licensed provider — fully eligible
• Telehealth consultation fees to obtain a GLP-1 prescription — fully eligible
• Lab work required before or during GLP-1 treatment — fully eligible
• Injection supplies (syringes, sharps containers) — fully eligible
• Over-the-counter weight loss supplements without a prescription — NOT eligible

HSA funds roll over year to year and can be invested, making them particularly powerful for planning long-term GLP-1 therapy. FSA funds typically have a "use it or lose it" rule by year-end (with a $640 carryover limit in 2026), so timing purchases matters. For guidance on the full cost structure of GLP-1 treatment, see our annual cost and maintenance guide for GLP-1.

Manufacturer Savings Programs in 2026

Both Novo Nordisk (maker of Wegovy and Ozempic) and Eli Lilly (maker of Zepbound and Mounjaro) offer manufacturer savings programs that can significantly reduce out-of-pocket costs for commercially insured patients. These are not available to Medicare or Medicaid beneficiaries under federal anti-kickback rules.

Manufacturer savings cards work at the pharmacy point of sale. Critically, some cards apply even if the insurer has denied coverage — you pay the card-covered amount for a cash-pay fill. Verify current terms directly with the manufacturer, as program eligibility and cap amounts change periodically.

If you have commercial insurance that covers GLP-1s but with a high-tier copay, manufacturer cards can essentially eliminate your cost-sharing. Discuss this option with your pharmacist at the time of fill. For a comprehensive overview of affordability strategies, read our guide on affordable GLP-1 injection options.

State-by-State Coverage Differences

State-level variation in GLP-1 coverage is driven primarily by Medicaid policy choices and, for ACA marketplace plans, whether the state has adopted broad essential health benefit interpretations. As of April 2026, the coverage landscape by state type looks as follows:

Medicaid Coverage by State Category

State insurance departments also influence commercial plans. In states with strong external review rights and independent review organization (IRO) infrastructure, denied patients have more robust appeal options than in states with weaker insurance oversight.

If your state has limited coverage and you're researching providers by geography, see our best GLP-1 providers by state guide which covers telehealth access options across all 50 states.

What If Insurance Says No: Compounded Alternatives

If your insurance won't cover GLP-1 medications — or if the cost-sharing after coverage is still unaffordable — compounded semaglutide and tirzepatide are legal, clinically sound alternatives that a substantial and growing number of patients use successfully.

How Compounded GLP-1s Work

Compounded GLP-1 medications are prepared by state-licensed 503B outsourcing facilities or PCAB-accredited compounding pharmacies. They contain the same active pharmaceutical ingredient — semaglutide or tirzepatide — as brand-name products. The STEP 1 trial showed 14.9% average weight loss with semaglutide (Wilding et al., NEJM 2021); the SURMOUNT-1 trial showed 20–22% weight loss with tirzepatide (Jastreboff et al., NEJM 2022). These clinical outcomes were achieved with the same molecule now available through compounding.

Compounded versions are not FDA-approved finished drug products and are not interchangeable with brand-name drugs under FDA regulations. However, they are legal under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act when dispensed pursuant to a valid prescription.

Comparing Insurance vs. Compounded Pathways

For a full safety and efficacy review of compounded semaglutide, read our article on compounded semaglutide safety in 2026. To compare the leading compounded GLP-1 telehealth providers, see our best compounded GLP-1 providers comparison.

Getting Started: Your Coverage Decision Flowchart

The right path depends on your current insurance situation. Use this framework to identify your best next step:

1. Step 1: Determine your coverage type

   Medicare? Employer plan? Medicaid? ACA marketplace? Uninsured? Each has a different primary strategy.

2. Step 2: Check your formulary and benefit exclusions

   Look up your plan's drug list for semaglutide, tirzepatide, Wegovy, Zepbound. Check for explicit obesity medication exclusions in the SBC.

3. Step 3: If covered, pursue PA with thorough documentation

   Work with your provider to submit a complete PA packet. Appeal any denial before switching strategies.

4. Step 4: If denied or excluded, evaluate cost pathways

   Check manufacturer savings cards (commercial insurance), PAP programs (uninsured), HSA/FSA availability, and compounded alternatives like Trimi ($99/mo).

5. Step 5: Consider the total cost of access, not just the drug price

   Factor in time lost to PA processes, PA denial stress, and ongoing monitoring costs when comparing insurance-covered brand vs. compounded telehealth programs.

For more on starting GLP-1 treatment and what to expect in the first months, see our complete GLP-1 guide and our overview of managing GLP-1 side effects. If you're comparing providers, our best GLP-1 provider comparison covers telehealth options across all major criteria.